Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tioxolone is a small molecule inhibitor of the metalloenzyme carbonic anhydrase I. It has been primarily used as a topical dermatological agent for the treatment of acne and psoriasis vulgaris. Tioxolone exhibits cytostatic, antipsoriatic, antibacterial, and anti-mycotic properties. Its mechanism involves binding to the active site of carbonic anhydrase I and inhibiting its enzymatic activity, which can affect processes such as pH regulation and sebum production in the skin. In addition to its medical uses, tioxolone is also included in some cosmetic products like shampoos and skin cleansers for its oil-regulating and antibacterial effects[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tioxolone.